Shionogi & Coの配当性向
Shionogi & Coの配当性向は何ですか。
Shionogi & Co., Ltd.の配当性向は0.00%です。
配当性向の定義は何ですか。
配当性向は、株主への配当で支払われる利益の割合です。
The payout ratio is calculated by dividing the dividends paid out by the net earnings for a certain period. It is usually expressed as a percentage. The part of the earnings not paid to investors is left for investment to provide for future earnings growth. Investors seeking high current income and limited capital growth prefer companies with high payout ratio. However investors seeking capital growth may prefer lower payout ratio because capital gains are taxed at a lower rate. High growth firms in early life generally have low or zero payout ratios. As they mature, they tend to return more of the earnings back to investors.
OTCのセクタHealth Careにおける配当性向の企業と比べるShionogi & Co
Shionogi & Coは何をしますか。
Shionogi & Co., Ltd. engages in the research, development, manufacture, and distribution of pharmaceuticals, diagnostic reagents, and medical devices in Japan. It offers Fetroja, a multidrug-resistant for gram-negative bacterial infection treatment; Xofluza, an influenza virus drug; and Tivicay for HIV treatment. It also develops Symproic for opioid-induced constipation treatment; S-120083 for Inflammatory pain; S-010887 for Neuropathic pain; S-117957 for Insomnia; sivopixant for Neuropathic pain, Sleep Apnea Syndrome, and Refractory/unexplainedchronic cough; S-637880 for Neuropathic Low Back Pain; Zuranolone for Depression; SDT-001 for attention-deficit/hyperactivity disorder patients; BPN14770 for Fragile X syndrome and Alzheimer's disease; and S-237648 and S-309309 for Obesity. In addition, the company develops ADR-001 for Decompensated liver cirrhosis; S-723595 for NASH; S-588410 for Esophageal and Bladder cancer; S-488210 for Head and neck squamouscell carcinoma; S-588210 for Solid tumor; S-222611 for Malignant tumor; S-770108 for Idiopathic pulmonary fibrosis; SR-0379 for Cutaneous ulcer; S-005151 for Stroke and Epidermolysis bullosa; S-531011 for Solid tumor; S-0373 for Spinocerebellar ataxia; and S-600918 and S-217622 for COVID-19, as well as S-555739 for Control of the aggravation of COVID-19. Further, it offers antibody test kits for COVID-19. Shionogi & Co., Ltd. has collaboration agreements with Nagasaki University, the National Institute of Infectious Diseases, and The Kitasato University to develop antimalarial drugs. The company was formerly known as Shionogi Shoten Co., Ltd. and changed its name to Shionogi & Co., Ltd. in 1943. Shionogi & Co., Ltd. was founded in 1878 and is headquartered in Osaka, Japan.
Shionogi & Coと類似の配当性向
- Artの配当性向は-0.30%です。
- Invesco Asia Trust Plcの配当性向は-0.22%です。
- Jindal Drilling & Industriesの配当性向は-0.20%です。
- Tern Propertiesの配当性向は-0.16%です。
- Henderson Smaller Cos. Investment Trust Plcの配当性向は-0.10%です。
- Pacific Horizon Investment Trust Plcの配当性向は-0.05%です。
- Shionogi & Coの配当性向は0.00%です。
- The Monks Investment Trust Plcの配当性向は0.01%です。
- Crestwood Equity Partners LPの配当性向は0.01%です。
- AVI Global Trust plcの配当性向は0.02%です。
- Artemis Alpha Trust plcの配当性向は0.03%です。
- Rights & Issues Investment Trust Plcの配当性向は0.04%です。
- Strategic Equity Capital Plcの配当性向は0.04%です。